Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Change in Account Payables (2016 - 2024)

Oramed Pharmaceuticals filings provide 13 years of Change in Account Payables readings, the most recent being $1.5 million for Q3 2024.

  • Quarterly Change in Account Payables fell 10.42% to $1.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Sep 2024, up 651.79% year-over-year, with the annual reading at -$2.2 million for FY2023, 491.76% down from the prior year.
  • Change in Account Payables hit $1.5 million in Q3 2024 for Oramed Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.2 million in Q2 2024 and bottomed at -$3.2 million in Q2 2023.
  • Average Change in Account Payables over 3 years is $174727.3, with a median of $389000.0 recorded in 2020.
  • Peak annual rise in Change in Account Payables hit 322.83% in 2020, while the deepest fall reached 1009.82% in 2020.
  • Oramed Pharmaceuticals' Change in Account Payables stood at $1.2 million in 2020, then plummeted by 154.12% to -$624000.0 in 2023, then surged by 347.92% to $1.5 million in 2024.
  • Per Business Quant, the three most recent readings for ORMP's Change in Account Payables are $1.5 million (Q3 2024), $2.2 million (Q2 2024), and -$666000.0 (Q1 2024).